皮肤冠状动脉干预后患有高缺血和出血风险的患者的最佳长期抗血小板治疗方案
Jeong Yoon Jang1, Ga-In Yu1, Jongwha Ahn1
1Cardiovascular Centre, Department of Internal Medicine, Gyeongsang National University School of Medicine, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea.
Thrombosis and haemostasis
|December 10, 2024
概括
对于皮肤冠状动脉干预 (PCI) 后高风险出血和缺血的患者,克洛皮多格雷尔单一治疗与双抗血小板治疗 (DAPT) 相比,提供了优越的长期抗血小板策略. 这种方法显著降低了死亡,心肌梗塞或中风的复合终点.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 接受穿皮冠状动脉干预 (PCI) 的患者经常面临缺血事件和出血并发症的双重风险.
- 优化长期抗血小板治疗对于在高风险人群中平衡疗效和安全至关重要.
- 目前的策略通常涉及双抗血小板治疗 (DAPT),但其长期使用可能会增加出血风险.
研究的目的:
- 评估PCI后患有缺血和出血高风险的患者的最佳长期抗血小板策略.
- 在这个特定的患者群体中,比较克洛皮多格雷尔单疗法 (CLPD),阿司匹林单疗法 (ASA) 和DAPT的临床结果.
主要方法:
- 采用了队列研究设计,包括患有高缺血和出血风险的患者,这些患者在没有并发症的情况下完成了强制性的DAPT期.
- 在三个治疗组中评估了临床结果:CLPD,ASA和DAPT.
- 稳定逆概率治疗权重 (IPTW) 用于调整基线特征和平衡治疗组.
主要成果:
- 在IPTW调整后,与DAPT (HR=2.09,p=0.008) 相比,克洛皮多格雷尔单疗法 (CLPD) 的初级复合终点 (全因死亡,心肌梗塞,中风或严重出血) 的比率明显较低 (HR=2.09,p=0.008).
- 在CLPD和阿司匹林单疗法 (ASA) 之间没有发现显著差异 (HR=1.46,p=0.187).
- 与DAPT相比,CLPD的好处主要是由于缺血事件的减少 (HR=2.51,p=0.003),并趋向于降低出血发生率 (HR=2.51,p=0.096).
结论:
- 克洛皮多格雷尔单一治疗对患有高出血和缺血风险的患者具有显著的临床净益处,特别是在复杂的PCI后.
- 这种策略在降低复合终点方面似乎优于DAPT,主要是由于缺血事件较少.
- 与阿司匹林单疗法相比,克洛皮多格雷尔单疗法也显示出出血和缺血事件的数值减少.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
468
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
468
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
616
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
616
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
01:22Formation of the Platelet Plug
4.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.4K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
141
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141
01:26Peptic Ulcer Disease IV: Management
72
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
72